135 related articles for article (PubMed ID: 35258855)
1. JACLS ALL-02 SR protocol reduced-intensity chemotherapy produces excellent outcomes in patients with low-risk childhood acute lymphoblastic leukemia.
Takahashi Y; Ishida H; Imamura T; Tamefusa K; Suenobu S; Usami I; Yumura-Yagi K; Hasegawa D; Nishimura S; Suzuki N; Hashii Y; Deguchi T; Moriya-Saito A; Kosaka Y; Kato K; Kobayashi R; Kawasaki H; Hori H; Sato A; Kudo T; Nakahata T; Oda M; Hara J; Horibe K
Int J Hematol; 2022 Jun; 115(6):890-897. PubMed ID: 35258855
[TBL] [Abstract][Full Text] [Related]
2. ETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol.
Wang Y; Zeng HM; Zhang LP
Ital J Pediatr; 2018 Aug; 44(1):94. PubMed ID: 30115129
[TBL] [Abstract][Full Text] [Related]
3. [Clinical features and prognosis of high hyperdiploid childhood acute lymphoblastic leukemia: a multicenter retrospective analysis in Fujian Province, China].
Cai CX; Zheng YZ; Li J; Wen H; Weng KZ; Zhuang SQ; Wu XG; LE SH
Zhongguo Dang Dai Er Ke Za Zhi; 2023 Jan; 25(1):38-45. PubMed ID: 36655662
[TBL] [Abstract][Full Text] [Related]
4. Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
Li XY; Li JQ; Luo XQ; Wu XD; Sun X; Xu HG; Li CG; Liu RY; Sun XF; Chen HQ; Lin YD; Li CK; Fang JP
BMC Cancer; 2021 Jan; 21(1):59. PubMed ID: 33435902
[TBL] [Abstract][Full Text] [Related]
5. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
6. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
7. Discontinuation of L-asparaginase and poor response to prednisolone are associated with poor outcome of ETV6-RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia.
Usami I; Imamura T; Takahashi Y; Suenobu SI; Hasegawa D; Hashii Y; Deguchi T; Hori T; Shimada A; Kato K; Ito E; Moriya-Saito A; Kawasaki H; Hori H; Yumura-Yagi K; Hara J; Sato A; Horibe K;
Int J Hematol; 2019 Apr; 109(4):477-482. PubMed ID: 30689137
[TBL] [Abstract][Full Text] [Related]
8. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
Cario G; Rhein P; Mitlöhner R; Zimmermann M; Bandapalli OR; Romey R; Moericke A; Ludwig WD; Ratei R; Muckenthaler MU; Kulozik AE; Schrappe M; Stanulla M; Karawajew L
Haematologica; 2014 Jan; 99(1):103-10. PubMed ID: 23911702
[TBL] [Abstract][Full Text] [Related]
9. [Long-term outcome of childhood T-cell acute lymphoblastic leukemia treated with modified national protocol of childhood leukemia in China-acute lymphoblastic leukemia 2008].
Liao C; Shen DY; Xu XJ; Xu WQ; Zhang JY; Song H; Yang SL; Zhao FY; Shen HP; Tang YM
Zhonghua Er Ke Za Zhi; 2020 Sep; 58(9):758-763. PubMed ID: 32872717
[No Abstract] [Full Text] [Related]
10. Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
Schrappe M; Bleckmann K; Zimmermann M; Biondi A; Möricke A; Locatelli F; Cario G; Rizzari C; Attarbaschi A; Valsecchi MG; Bartram CR; Barisone E; Niggli F; Niemeyer C; Testi AM; Mann G; Ziino O; Schäfer B; Panzer-Grümayer R; Beier R; Parasole R; Göhring G; Ludwig WD; Casale F; Schlegel PG; Basso G; Conter V
J Clin Oncol; 2018 Jan; 36(3):244-253. PubMed ID: 29148893
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcomes for childhood acute lymphoblastic leukemia in low-middle income country before minimal residual disease risk stratification.
Makkeyah S; Manzour A; Tantawy A; Mohamed A; Ebeid F; El-Sherif N; Abd El-Ghany S; Shawiesh M; Ali H; Sayed S; Ragab I
Cancer Epidemiol; 2021 Dec; 75():102040. PubMed ID: 34649157
[TBL] [Abstract][Full Text] [Related]
12. Outcome of TCF3-PBX1 positive pediatric acute lymphoblastic leukemia patients in Japan: a collaborative study of Japan Association of Childhood Leukemia Study (JACLS) and Children's Cancer and Leukemia Study Group (CCLSG).
Asai D; Imamura T; Yamashita Y; Suenobu S; Moriya-Saito A; Hasegawa D; Deguchi T; Hashii Y; Endo M; Hatakeyama N; Kawasaki H; Hori H; Horibe K; Yumura-Yagi K; Hara J; Watanabe A; Kikuta A; Oda M; Sato A;
Cancer Med; 2014 Jun; 3(3):623-31. PubMed ID: 24578304
[TBL] [Abstract][Full Text] [Related]
13. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
[TBL] [Abstract][Full Text] [Related]
14. Favorable Trisomies and
Mattano LA; Devidas M; Maloney KW; Wang C; Friedmann AM; Buckley P; Borowitz MJ; Carroll AJ; Gastier-Foster JM; Heerema NA; Kadan-Lottick NS; Matloub YH; Marshall DT; Stork LC; Loh ML; Raetz EA; Wood BL; Hunger SP; Carroll WL; Winick NJ
J Clin Oncol; 2021 May; 39(14):1540-1552. PubMed ID: 33739852
[TBL] [Abstract][Full Text] [Related]
15. Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group.
Heerema NA; Carroll AJ; Devidas M; Loh ML; Borowitz MJ; Gastier-Foster JM; Larsen EC; Mattano LA; Maloney KW; Willman CL; Wood BL; Winick NJ; Carroll WL; Hunger SP; Raetz EA
J Clin Oncol; 2013 Sep; 31(27):3397-402. PubMed ID: 23940221
[TBL] [Abstract][Full Text] [Related]
16. Differing Outcomes of Patients with High Hyperdiploidy and ETV6-RUNX1 Rearrangement in Korean Pediatric Precursor B Cell Acute Lymphoblastic Leukemia.
Lee JW; Kim S; Jang PS; Chung NG; Cho B
Cancer Res Treat; 2021 Apr; 53(2):567-575. PubMed ID: 33070555
[TBL] [Abstract][Full Text] [Related]
17. Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: The first nation-wide prospective multicenter study in China.
Cui L; Li ZG; Chai YH; Yu J; Gao J; Zhu XF; Jin RM; Shi XD; Zhang LP; Gao YJ; Zhang RD; Zheng HY; Hu SY; Cui YH; Zhu YP; Zou Y; Ng MHL; Xiao Y; Li JH; Zhang YH; He HL; Xian Y; Wang TY; Li CK; Wu MY;
Am J Hematol; 2018 Jul; 93(7):913-920. PubMed ID: 29675840
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
19. ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy.
Bhojwani D; Pei D; Sandlund JT; Jeha S; Ribeiro RC; Rubnitz JE; Raimondi SC; Shurtleff S; Onciu M; Cheng C; Coustan-Smith E; Bowman WP; Howard SC; Metzger ML; Inaba H; Leung W; Evans WE; Campana D; Relling MV; Pui CH
Leukemia; 2012 Feb; 26(2):265-70. PubMed ID: 21869842
[TBL] [Abstract][Full Text] [Related]
20. Improved Outcome for ALL by Prolonging Therapy for
Pieters R; de Groot-Kruseman H; Fiocco M; Verwer F; Van Overveld M; Sonneveld E; van der Velden V; Beverloo HB; Bierings M; Dors N; de Haas V; Hoogerbrugge P; Van der Sluis I; Tissing W; Veening M; Boer J; Den Boer M
J Clin Oncol; 2023 Sep; 41(25):4130-4142. PubMed ID: 37459571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
